ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides

August 9, 2024

https://www.globenewswire.com/news-release/2024/08/09/2927628/0/en/ANEW-MEDICAL-INC-Pursues-Neurological-Approach-to-Treating-Weight-Loss-and-Eating-Disorders-through-Melanocortin-Receptor-Binding-Peptides.html

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) — ANEW MEDICAL, INC. (NASDAQ:WENA) has announced that, as a result of its worldwide licensing agreement with Teleost Biopharmaceuticals and the University of Arizona, it plans to pursue the development of therapeutics using novel proprietary peptides that selectively bind and activate melanocortin receptors on neuronal cells in the brain. The neurobiology of overeating and obesity is well known, and the melanocortin-3 and melanocortin-4 receptors are definitively involved in the control of eating disorders and obesity.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.